Metraipolis › archive › dc_bf3c72dc83c5

Real-world outcomes for selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas in Japan: A 1-year interim analysis — Europe PMC PMID:41847168

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41847168
DOI
10.1093/noajnl/vdag042
License (as archived)
solo-consultazione
Archived
2026-11-07T05:33:22.758Z
SHA-256 of the archived text
88a401fc18aa1eedea6565b2f3b9033cadb0a69cc8f62ade58f8a237d96e881f
Stable URL of this page
https://metraipolis.com/documento/dc_bf3c72dc83c5

How to cite

Real-world outcomes for selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas in Japan: A 1-year interim analysis — Europe PMC PMID:41847168 — Europe PMC (en), https://europepmc.org/article/MED/41847168 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bf3c72dc83c5 (Metraipolis archive dc_bf3c72dc83c5, sha256 88a401fc18aa1eedea6565b2f3b9033cadb0a69cc8f62ade58f8a237d96e881f)
BibTeX
@misc{dcbf3c72dc83c5,
  title = {Real-world outcomes for selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas in Japan: A 1-year interim analysis — Europe PMC PMID:41847168},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41847168},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bf3c72dc83c5; sha256 88a401fc18aa1eedea6565b2f3b9033cadb0a69cc8f62ade58f8a237d96e881f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41847168. Agents can read the archived copy with the MCP tool read_document.